New vaccine aims to train immune system against lung cancer

This study tests a vaccine designed to help the immune system recognize and attack non-small cell lung cancer. The vaccine uses a piece of the MUC1 protein, which is often found on cancer cells, mixed with an immune booster called Poly-ICLC. About 30 adults with stable, early or locally advanced lung cancer will receive three vaccine shots every three weeks, with optional yearly boosters for up to five years. The main goal is to see if the vaccine triggers a strong immune response against MUC1.